For example, among the 3.2% of individuals who reported hypertension as a primary disease and lung disease as a competing disease, 60.4% used beta-blockers, and 56.9% used angiotensin-converting enzyme inhibitors (Table 3). This evidence concerns the gene ACE and lung disorder.